Avadel Pharmaceuticals PLC (AVDL) Receives $2.00 Consensus Price Target from Analysts

Shares of Avadel Pharmaceuticals PLC (NASDAQ:AVDL) have been given a consensus recommendation of “Hold” by the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and six have assigned a hold rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $2.00.

AVDL has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Avadel Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday. Laidlaw set a $2.00 target price on shares of Avadel Pharmaceuticals and gave the stock a “hold” rating in a report on Monday, March 18th. Finally, LADENBURG THALM/SH SH downgraded shares of Avadel Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Friday, February 8th.

Hedge funds have recently modified their holdings of the company. HRT Financial LLC purchased a new stake in shares of Avadel Pharmaceuticals during the fourth quarter worth about $33,000. Wedbush Securities Inc. purchased a new stake in shares of Avadel Pharmaceuticals during the first quarter worth about $51,000. Paloma Partners Management Co purchased a new stake in shares of Avadel Pharmaceuticals during the fourth quarter worth about $59,000. Millennium Management LLC purchased a new stake in shares of Avadel Pharmaceuticals during the fourth quarter worth about $189,000. Finally, Highbridge Capital Management LLC purchased a new stake in shares of Avadel Pharmaceuticals during the fourth quarter worth about $253,000. Institutional investors and hedge funds own 53.35% of the company’s stock.

Avadel Pharmaceuticals stock traded up $0.01 during trading hours on Wednesday, reaching $1.32. The stock had a trading volume of 88,900 shares, compared to its average volume of 163,931. The company has a market capitalization of $46.64 million, a PE ratio of -0.66 and a beta of 1.69. The company has a debt-to-equity ratio of 41.63, a quick ratio of 3.13 and a current ratio of 3.27. Avadel Pharmaceuticals has a 52 week low of $1.03 and a 52 week high of $7.97.

Avadel Pharmaceuticals (NASDAQ:AVDL) last announced its earnings results on Wednesday, May 8th. The company reported ($0.35) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.05. The business had revenue of $16.44 million during the quarter. Avadel Pharmaceuticals had a negative net margin of 111.19% and a negative return on equity of 215.96%. On average, equities analysts predict that Avadel Pharmaceuticals will post -1.39 earnings per share for the current fiscal year.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria.

Featured Story: Understanding Specialty Certificates of Deposit

Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.